Source-grounded facts extracted from Matinas BioPharma Holdings, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Matinas BioPharma Holdings, Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).
“April 2, 2026, Matinas BioPharma Holdings, Inc. (the “Company”) received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to ha”
Governance Changes
Matinas BioPharma Holdings, Inc.: Increased authorized shares of common stock from 250,000,000 to 500,000,000 (effective 2025-08-06).
“On August 6, 2025, Matinas BioPharma Holdings, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company’s common stock from 250,000,000 shares to 500,000,000 shares. The Certificate of Amendment was approved by the Company’s stockholders at the 2025 annual meeting on June 23, 2025 and became effective upon filing.”
Eric Ende resigned as Chairman of the Board at Matinas BioPharma Holdings, Inc..
“On March 13, 2025, Eric Ende informed the Board of Directors (the “ Board ”) of Matinas BioPharma Holdings, Inc. (the “ Company ”) that he was resigning as a member of the Board and as Chairman of the Board effective March 14, 2025, due to his other professional obligations.”
Edward Neugeboren was appointed as Director at Matinas BioPharma Holdings, Inc..
“The Board appointed Mr. Neugeboren to serve as a member of the Audit Committee and as Chair of the Compensation Committee.”
Keith Murphy was appointed as Director at Matinas BioPharma Holdings, Inc..
“Effective as of March 11, 2025, the Board, on the recommendation of the Governance Committee, appointed Keith Murphy and Edward Neugeboren directors of the Company to replace Ms. Giordano and Mr. Wikler, respectively.”
Matthew Wikler resigned as Director at Matinas BioPharma Holdings, Inc..
“On February 10, 2025, Matthew Wikler informed the Board that he was resigning from the Board effective February 11, 2025, due to his other professional obligations.”
Natasha Giordano resigned as Director at Matinas BioPharma Holdings, Inc..
“On February 10, 2025, Natasha Giordano informed the Board of Directors (the “ Board ”) of Matinas BioPharma Holdings, Inc. (the “ Company ”) that she was resigning from the Board effective February 11, 2025, due to her other professional obligations.”
Robin Smith was appointed as Director at Matinas BioPharma Holdings, Inc..
“the Board, on the recommendation of its Nominating and Corporate Governance Committee, appointed Robin Smith director of the Company.”
Herbert Conrad resigned as Director at Matinas BioPharma Holdings, Inc..
“On February 5, 2025, Herbert Conrad informed the Board of Directors (the “ Board ”) of Matinas BioPharma Holdings, Inc. (the “ Company ”) that he was resigning from the Board effective February 6, 2025, due to retirement.”
Listing & Compliance Notices
Matinas BioPharma Holdings, Inc. received a nyse_american deficiency notice notice regarding other.
“January 6, 2025, Matinas BioPharma Holdings, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the NYSE American LLC (“NYSE American”) stating that the Company failed to hold an annual meeting of stoc”
James Ferguson was terminated as Chief Medical Officer at Matinas BioPharma Holdings, Inc..
“the employment of James Ferguson, M.D., the Company’s Chief Medical Officer, was terminated effective October 31, 2024.”
Earnings Releases
Matinas BioPharma Holdings, Inc. reported the three months ending March 31, 2024 results: revenue no revenue for the first quarter of 2024, net income net loss for the first quarter of 2024 was $5.8 million, or $0.03 per share, EPS $0.03 per share.
“Matinas BioPharma Holdings, Inc . (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three months ending March 31, 2024 and provides a business update.”
Material Agreements
Matinas BioPharma Holdings, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at Placement agent to use reasonable best efforts to sell securities; cash fee of 7.0% of aggregate pur (effective 2024-04-02).
“On April 2, 2024, the Company also entered into a placement agent agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”).”
Material Agreements
Matinas BioPharma Holdings, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at 33,333,334 shares of common stock and warrants to purchase 33,333,334 shares of common stock at offe (effective 2024-04-02).
“On April 2, 2024, Matinas BioPharma Holdings, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (collectively, the “Purchasers”).”
Earnings Releases
Matinas BioPharma Holdings, Inc. reported financial results for for the year and quarter ended December 31, 2023.
“On March 27, 2024, Matinas BioPharma Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the year and quarter ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.